Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02001974 |
|
Recruitment Status :
Completed
First Posted : December 5, 2013
Last Update Posted : July 1, 2015
|
Sponsor:
Dompé Farmaceutici S.p.A
Collaborator:
PRA Health Sciences
Information provided by (Responsible Party):
Dompé Farmaceutici S.p.A
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet
publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending
Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during
QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review
assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific
validity or relevance of the submitted information.
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | October 2014 |
| Actual Study Completion Date : | June 2015 |
| Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
|---|---|---|
| 1 |
February 4, 2021 | February 26, 2021 |
| 2 |
March 23, 2021 |